Epigenetic regulation of cancer/germ-line antigen gene expression

癌症/种系抗原基因表达的表观遗传调控

• 批准号: 7230469
• 负责人: ADAM R. KARPF
• 金额: $ 27.29万
• 依托单位: ROSWELL PARK CANCER INSTITUTE CORP
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-05-08 至 2011-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7230469
• 关键词: Address; Antigens; Appendix; Biochemical; Biochemical Genetics; Biological Models; CTAG1 gene; Cancer Control; Cancer Model; Cancer Patient; Cancer Vaccines; Cell model; Clinical; Clinical Treatment; Clinical Trials; Clinical Trials Design; Complement component C4; Correlation Studies; CpG Islands; Cytosine; DNA; DNA Methylation; DNA Methyltransferase; DNA Modification Methylases; Data; Defect; Development; Disruption; Enzymes; Epigenetic Process; Epithelial ovarian cancer; Formalin; Freezing; Future; G9a histone methyltransferase; Gene Activation; Gene Expression; Gene Expression Regulation; Gene Family; Gene Silencing; Genes; Genetic Models; Genomic Instability; Genomics; Germ Lines; HLA Antigens; Histone H3; Histones; Histopathology; Human; Immunotherapy; In Vitro; Investigation; Knock-out; Lysine; Malignant Neoplasms; Malignant neoplasm of ovary; Mammalian Cell; Mass Spectrum Analysis; Mediating; Methods; Methylation; Modeling; Modification; Molecular; Molecular Genetics; Mus; Oncogene Activation; Orthologous Gene; Outcome; Paraffin Embedding; Patients; Pattern; Play; Proteins; Public Health; Regulation; Repression; Research Personnel; Role; Role playing therapy; Series; Staining method; Stains; Tail; Testing; Tissue Banks; Tissues; Tumor Antigens; Tumor-Suppressor Gene Inactivation; Vaccines; base; cancer cell; cancer therapy; cancer type; cell mediated immune response; clinically relevant; design; gene repression; genetic inhibitor; histone methyltransferase; improved; in vivo; knowledge base; melanoma-associated antigen-A1; novel; promoter; tumor; tumorigenesis

DESCRIPTION (provided by applicant): Epigenetic changes, particularly alterations in DNA methylation, contribute to oncogenesis in at least two respects. First, overall DNA methylation is reduced in tumors, which leads to aberrant gene activation and genomic instability. Second, CpG island promoters become hypermethylated, which leads to transcriptional silencing and the functional inactivation of tumor suppressor genes. In addition to changes in DNA methylation, other important epigenetic changes have been observed in human cancer, including alterations in histone modification patterns and histone modifying enzymes. Our long-term objective is to understand the molecular mechanisms that initiate and maintain abnormal epigenetic states in human cancer. To meet this objective, we are utilizing cancer/germ-line (CG) antigen genes as models. CG antigens are an intriguing gene family whose aberrant expression in human cancer appears to result from epigenetic deregulation. In addition, CG antigens are HLA-restricted tumor antigens that trigger humoral and cell- mediated immune responses in cancer patients; CG antigen directed vaccines are currently in numerous human clinical trials. Thus, in addition to serving as a model for understanding epigenetic deregulation in cancer, CG antigens are clinically relevant. We hypothesize that CG antigen gene expression is epigenetically regulated by the action of specific DNA methyltransferases (DNMTs) and histone methyltransferases. To test this hypothesis, we will pursue four complementary and unified specific aims: 1) Determine the mechanism by which DNMTs repress CG antigen gene expression in human cancer cells; 2) Define the histone H3 tail lysine modifications that control CG antigen gene expression in human cancer cells; 3) Ascertain the role of the histone methyltransferases G9a and Eu-HMTasel in CG antigen gene regulation in human cancer cells; and 4) Determine whether NY-ESO-1 expression is associated with DNA hypomethylation in epithelial ovarian cancer. This study will impact public health by improving our understanding of why only certain patients express clinically important cancer vaccine targets. Furthermore, this study will provide key information relevant for understanding the outcome and improving the future design of clinical vaccine trials for the treatment of ovarian cancer.

描述（由申请人提供）：表观遗传学变化，特别是DNA甲基化的改变，至少在两个方面促进肿瘤发生。首先，肿瘤中的总体DNA甲基化降低，这导致异常基因激活和基因组不稳定性。第二，CpG岛启动子变得高甲基化，这导致转录沉默和肿瘤抑制基因的功能失活。除了DNA甲基化的变化外，在人类癌症中还观察到其他重要的表观遗传变化，包括组蛋白修饰模式和组蛋白修饰酶的改变。我们的长期目标是了解启动和维持人类癌症异常表观遗传状态的分子机制。为了实现这一目标，我们正在利用癌症/生殖系（CG）抗原基因作为模型。CG抗原是一个有趣的基因家族，其在人类癌症中的异常表达似乎是由于表观遗传失调。此外，CG抗原是在癌症患者中触发体液和细胞介导的免疫应答的HLA限制性肿瘤抗原; CG抗原导向的疫苗目前处于许多人类临床试验中。因此，除了作为理解癌症中表观遗传失调的模型之外，CG抗原在临床上是相关的。我们假设CG抗原基因表达是由特异性DNA甲基转移酶（DNMT）和组蛋白甲基转移酶的作用表观遗传调控。为了验证这一假设，我们将追求四个互补和统一的具体目标：1）确定DNMT抑制人癌细胞中CG抗原基因表达的机制; 2）确定控制人癌细胞中CG抗原基因表达的组蛋白H3尾赖氨酸修饰; 3）确定组蛋白甲基转移酶G9 a和Eu-HMTasel在人癌细胞中CG抗原基因调控中的作用;以及4）确定NY-ESO-1表达是否与上皮性卵巢癌中DNA低甲基化相关。这项研究将通过提高我们对为什么只有某些患者表达临床上重要的癌症疫苗靶点的理解来影响公共卫生。此外，这项研究将提供关键信息，了解结果和改善未来设计的临床疫苗试验治疗卵巢癌。